Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Retained Earnings (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Retained Earnings for 15 consecutive years, with $10.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 3914.63% year-over-year to $10.5 million, compared with a TTM value of $10.5 million through Oct 2025, up 3914.63%, and an annual FY2025 reading of $10.5 million, up 3914.63% over the prior year.
  • Retained Earnings was $10.5 million for Q4 2025 at Pharma-Bio Serv, up from $285577.0 in the prior quarter.
  • Across five years, Retained Earnings topped out at $20.3 million in Q2 2021 and bottomed at $194377.0 in Q3 2021.
  • Average Retained Earnings over 5 years is $8.9 million, with a median of $10.7 million recorded in 2025.
  • Peak annual rise in Retained Earnings hit 19780.87% in 2021, while the deepest fall reached 99.09% in 2021.
  • Year by year, Retained Earnings stood at $17.7 million in 2021, then crashed by 98.66% to $238152.0 in 2022, then dropped by 11.71% to $210266.0 in 2023, then rose by 24.78% to $262380.0 in 2024, then skyrocketed by 3914.63% to $10.5 million in 2025.
  • Business Quant data shows Retained Earnings for PBSV at $10.5 million in Q4 2025, $285577.0 in Q3 2025, and $10.7 million in Q2 2025.